Michael Mauro, MD, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center explains essential thrombocythemia and the future of treatment and management of the disease.

Accredited CME from Imedex

Newly emerging evidence is informing best care for patients with polycythemia vera (PV). Not only are recently updated diagnostic criteria available for PV, but better ways to assess risk of thrombosis and disease progression are being discovered.
Ongoing discoveries continue to lead to preclinical breakthroughs and clinical advances in how MPN and MDS are diagnosed and treated.
Advances in both preclinical science and clinical management practices continue to change how MPN and MDS are diagnosed and treated.

Conferences

This Expert Perspectives discussion features a panel of experts summarizing the key take-home points from their presentations during the JAK Inhibitors in Myeloproliferative Neoplasms symposium.
Drs Joseph R Mikhael and Ruben A Mesa analyze and discuss pertinent clinical studies and late breaking updates pertaining the care of patients with chronic myelogenous leukemia and myeloproliferative neoplasms.
Recent advances in understanding the biology of MPN have spurred significant discoveries that have the potential to change the paradigm of how MPN and MDS are diagnosed and treated.
This online enduring activity provides a summary of the most intriguing and clinically applicable topics and data, outlines key learning points, and reinforces the take-home messages from the 2016 European Focus on Myeloproliferative Neoplasms & Myelodysplastic Syndromes.

Interviews

Michael Mauro, MD, leader of the Myeloproliferative Neoplasms Program at Memorial Sloan Kettering Cancer Center explains essential thrombocythemia and the future of treatment and management of the disease.
Angela G Fleischman, MD, discusses the role of inflammation in myeloproliferative neoplasm transition to leukemia.
Journal of Clinical Pathways spoke with Christoph Menzel, PhD, Director of Global Product Management MDx, Qiagen, about the implications of the ipsogen JAK2 assay FDA approval and the importance of JAK2 testing to support treatment decision-making for MPNs.

News

Patients with myelodysplastic syndromes experience a high distress burden, which negatively impacts clinical outcomes.
Patients with myelofibrosis who discontinue therapy have a median survival of only 14 months.
A JAK2/FLT3 inhibitor may be able to provide an alternative treatment option for patients with myelofibrosis and baseline thrombocytopenia.
The use of a JAK inhibitor prior to allogenic hematopoietic stem cell transplantation appears to be effective for patients with myelofibrosis.

Quiz

Updated NCCN guidelines for myeloproliferative neoplasms offer which of the following options for the management of myelofibrosis-associated anemia?

Resources

This new interactive feature allows you to review the treatment options for low-risk primary myelofibrosis, share your approach to determining the highest value treatment, and help to build a consensus clinical pathway for this disease.
The National Comprehensive Cancer Network has released updates to their guidelines for myeloproliferative neoplasms, including management suggestions for related disorders and testing options.

Slideshow

Within the past 3 months, the treatment landscapes for myeloproliferative neoplasms have been evolving, with multiple updates to procedures, practices, and guidelines.
Subscribe to Myeloproliferative Neoplasms